Antibody neutralization of coronaviruses

冠状病毒的抗体中和

• 批准号: 10272309
• 负责人: Theodore Pierson
• 金额: $ 20.26万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10272309
• 关键词: 2019-nCoV; Affect; Antibodies; Antibody Response; Clinical; Coronavirus; Coughing; Country; Disease; Fever; Goals; Heart failure; Infection; Mechanical ventilation; Outcome; RNA Viruses; Respiratory Failure; Shortness of Breath; Specificity; Syndrome; Vaccination; Vaccines; Virion; Vulnerable Populations; insight; neutralizing antibody; pandemic disease; transmission process; vaccine development; virtual

SARS-CoV-2 is a positive-sense single-stranded RNA virus first isolated in December of 2019. SARS-CoV-2 infection results in a clinical syndrome, coronavirus-induced disease-19 (COVID-19), which is characterized by fever, cough, and shortness of breath that can progress rapidly to respiratory and cardiac failure requiring mechanical ventilation. Virtually all countries and territories have since been affected. Rapid implementation and deployment of an effective SARS-CoV-2 vaccine has the potential to lessen the deleterious effects of infection, especially in vulnerable populations, curb transmission, and end the pandemic. Antibodies are hypothesized to contribute to protection from SARS-CoV-2 infection and COVID-19. The specificities and mechanisms of a protective antibody response have not been established and will be explored in this project.

SARS-CoV-2是一种正义单链RNA病毒，于2019年12月首次分离。SARS-CoV-2感染导致一种临床综合征，即冠状病毒诱导的疾病-19（COVID-19），其特征是发热、咳嗽和呼吸急促，可迅速进展为呼吸和心力衰竭，需要机械通气。几乎所有国家和领土都受到影响。快速实施和部署有效的SARS-CoV-2疫苗有可能减轻感染的有害影响，特别是在脆弱人群中，遏制传播，并结束大流行。假设抗体有助于保护免受SARS-CoV-2感染和COVID-19。保护性抗体反应的特异性和机制尚未确定，将在本项目中进行探索。